Generated: May 28, 2017
|Title:||Controlled sustained release tablets containing bupropion|
|Abstract:||A controlled sustained release tablet having at least one year shelf life and containing bupropion hydrochloride, hydroxypropyl methylcellulose and cysteine hydrochloride or glycine hydrochloride with the tablet having a surface area to volume ratio to effectively control bupropion hydrochloride release in the body.|
|Inventor(s):||Ludwig; Jennie Sue G. (Greenville, NC), Bass, Jr.; William L. (Farmville, NC), Sutton, Jr.; Joel E. (Greenville, NC)|
|Assignee:||Burroughs Wellcome Co. (Research Triangle Park, NC)|
Patent Claim Types:|
see list of patent claims
|Compound; Dosage form;|
|Foriegn Application Priority Data|
|Foreign Country||Foreign Patent Number||Foreign Patent Date|
|United Kingdom||9217295||Aug 14, 1992|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.